Clinical trial
Cost-effectiveness Study of Epoetin Alfa and Darbepoetin Alfa in Adult Patients…
NCT00264108 · Janssen-Cilag B.V., Industry · Completed
Key facts
| NCT number | NCT00264108 |
|---|---|
| Title | Cost-effectiveness Study of Epoetin Alfa and Darbepoetin Alfa in Adult Patients With Cancer Who Have Anemia |
| Official title | EPREX (Epoetin Alfa) Versus ARANESP (Darbepoetin Alfa): Looking at Outcome of Anemia Treatment and Comparing Cost-effectiveness (EVALUATE). |
| Lead sponsor | Janssen-Cilag B.V., Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Anemia, Neoplasms |
| Intervention type | Drug |
| Interventions | Darbepoetin alfa, Epoetin alfa |
| Enrollment | 492 |
| Start date | Jun 1, 2005 |
| Primary completion | Feb 1, 2011 |
| Completion | Feb 1, 2011 |
| First posted | Dec 12, 2005 |
| Last update posted | May 7, 2014 |
| Countries | Netherlands |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: